deoxycytidine has been researched along with Lymphoma, B-Cell in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Hino, T; Honda, A; Kurokawa, M; Masamoto, Y; Shimura, A | 1 |
| Bai, O; Guo, W; Liu, Z; Song, W; Tang, Z; Wang, S; Yu, H; Zhang, D | 1 |
| Duan, X; Fang, Y; Fang, Z; Lin, D; Liu, H; Luo, M; Miao, C; Wu, J; Zhang, X; Zhong, W | 1 |
| Eyre, TA | 1 |
| Chen, SB; Chen, ZG; Jie, GT; Lyu, X; Ma, DL; Wang, YL; Yan, SB | 1 |
| Fuse, K; Kawamoto, K; Kiryu, M; Masuko, M; Mitobe, M; Miyoshi, H; Nanba, A; Ohshima, K; Shibasaki, Y; Sone, H; Suwabe, T; Suzuki, T; Takizawa, J; Tamura, S; Tanaka, T | 1 |
| Franch-Sarto, M; López, L; Moreno, M; Ribera, JM; Sancho, JM; Sorigue, M | 1 |
| Clair, PM; Deininger, MW; Glenn, MJ; Kopeček, J; Kosak, KM; Li, L; Radford, DC; Shami, PJ; Stephens, DM; Wang, J; Yang, J | 1 |
| Cao, M; Chen, YC; Fan, ZF; Hu, SY; Li, WX; Liu, L; Sun, XM; Wang, LX; Yang, ZF; Zhou, JY; Zhu, XJ | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Keating, GM | 1 |
| Han, Y; Ni, S; Qiu, L; Zhang, G; Zhou, H | 1 |
| Arcamone, M; Ballerini, PF; Becchimanzi, C; Capobianco, G; Corazzelli, G; De Chiara, A; Frigeri, F; Iannitto, E; Marcacci, G; Pinto, A; Russo, F | 1 |
| Ba, Y; Hou, Y; Wang, HQ | 1 |
| Bonavida, B; Emmanouilides, C; Jazirehi, AR | 1 |
| Archer, CD; Catovsky, D; Chau, I; Cunningham, D; Gill, K; Harries, M; Hill, M; Koh, DM; Norman, AR; Prior, Y; Ross, PJ; Uzzell, M; Wotherspoon, A | 1 |
| Hsu, D; Lindgren, T; Tran, G; Wong, SF | 1 |
| Economopoulos, T; Fountzilas, G; Raptis, S; Rontogianni, D; Valsami, S; Xiros, N | 1 |
| Delecluse, HJ; Feng, WH; Hong, G; Kenney, SC | 1 |
| Colovos, C; Emmanouilides, C; Hernandez, L; Pinter-Brown, L; Rosen, P; Schiller, G; Territo, M | 1 |
| Crump, M; Lin, B; Shepherd, L | 1 |
| Dimopoulos, M; Economopoulos, T; Fountzilas, G; Papageorgiou, ES; Papageorgiou, S; Pavlidis, N; Tsirigotis, P | 1 |
| Capobianco, G; Corazzelli, G; Della Cioppa, P; Marcacci, G; Pinto, A; Russo, F | 1 |
| Arnaud, P; Bordier, V; Couturier, J; Decaudin, D; Lantz, O; Marszak, FB; Martin, A; Mathiot, C; Némati, F; Poupon, MF; Santo, Jd; Vincent-Salomon, A | 1 |
| Belhadj, K; Copie-Bergman, C; Diviné, M; Dupuis, J; El Gnaoui, T; Gaillard, I; Haioun, C; Jais, JP; Rahmouni, A; Reyes, F; Tabah-Fisch, I | 1 |
1 review(s) available for deoxycytidine and Lymphoma, B-Cell
| Article | Year |
|---|---|
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Topics: Adult; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
6 trial(s) available for deoxycytidine and Lymphoma, B-Cell
| Article | Year |
|---|---|
[Efficacy Analysis of GEMOX Regimen for Treatment of Refractory Non-Hodgkin's Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Rate | 2003 |
Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pilot Projects; Racial Groups; Recurrence | 2004 |
A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytarabine; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Rituximab | 2005 |
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2005 |
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Rituximab; Salvage Therapy; Survival Rate | 2007 |
19 other study(ies) available for deoxycytidine and Lymphoma, B-Cell
| Article | Year |
|---|---|
R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Retrospective Studies; Survival Rate | 2022 |
Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Polyethylene Glycol Complex Nanoparticles Combined with Gemcitabine Presents Improved Safety and Lasting Anti-Tumor Efficacy in a Murine Xenograft Model of Human Aggressive B Cell Lymphoma.
Topics: Animals; Animals, Outbred Strains; Cisplatin; Deoxycytidine; Gemcitabine; Glutamic Acid; Heterografts; Humans; Lymphoma, B-Cell; Mice; Mice, SCID; Nanoparticles; Polyethylene Glycols | 2021 |
Redox-responsive self-assembled polymeric nanoprodrug for delivery of gemcitabine in B-cell lymphoma therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lymphoma; Lymphoma, B-Cell; Mice; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Polymers; Prodrugs; Tumor Microenvironment | 2022 |
Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas.
Topics: B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Rituximab | 2020 |
Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Dexamethasone; DNA-Binding Proteins; Female; Gemcitabine; Gene Rearrangement; Humans; Lymphoma, B-Cell; Middle Aged; Salvage Therapy; Treatment Outcome | 2019 |
Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Oxaliplatin; Retrospective Studies; Rituximab | 2019 |
Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD20; Apoptosis; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Membrane Potential, Mitochondrial; Microscopy, Confocal; Middle Aged; Nanomedicine; Young Adult | 2019 |
Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Combined Modality Therapy; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Immunotherapy; Injections, Intralesional; Killer Cells, Natural; Lymphoma, B-Cell; Male; Mice; Mice, Inbred BALB C; Myeloid Cells; Survival Analysis; T-Lymphocytes, Cytotoxic; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |
Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lipids; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanostructures; Tissue Distribution; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Rituximab | 2012 |
Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma, B-Cell; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Low-dose gemcitabine plus cisplatin in previously treated, relapsed non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Salvage Therapy | 2003 |
Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Remission Induction; Rituximab; Salvage Therapy; T-Lymphocytes; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Topics: Animals; Antibiotics, Antineoplastic; Antiviral Agents; B-Lymphocytes; Cell Line, Transformed; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Lymphoma, B-Cell; Mice; Mice, SCID; Signal Transduction; Tumor Cells, Cultured; Virus Activation | 2004 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Hodgkin Disease; Homeodomain Proteins; Humans; Immunoglobulin Heavy Chains; Lymph Nodes; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Mice, Knockout; Mice, SCID; Nucleic Acid Hybridization; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |